Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
Philip J. Mease(Providence College), Subhashis Banerjee(Bristol-Myers Squibb (United States)), Atul Deodhar(Oregon Health & Science University), Alan Kivitz(Altoona Center for Clinical Research), Shalabh Singhal(Integrated BioTherapeutics (United States)), Jonghyeon Kim, Désirée van der Heijde(Leiden University Medical Center), Miroslawa Nowak(Bristol-Myers Squibb (United States)), Jeffrey Neal(University of Kentucky), Frank Behrens(Goethe University Frankfurt)
Cited by 212
Related Papers
The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity
|Arthritis Care & Research|2010|3.9k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
|The Lancet|2004|1.8k
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
|Annals of the Rheumatic Diseases|2017|1.6k